Clinical Trials Browser

HER2-positive Gastric Cancer × disitamab vedotin × Gastrointestinal × Clear all

NCT05586061 2025-02-07

RCTS

Phase 2 Active not recruiting

Gastrointestinal

HER2-positive Gastric Cancer

NCT06492317 2024-07-09

RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer

Phase 2 Not yet recruiting

Gastrointestinal

HER2-positive Gastric Cancer